1. Claus EB, Risch N and Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 73: 643-51, 1994.
2. National Cancer Institute. Breast Cancer Risk Assessment Tool. http://www.cancer.gov/bcrisktool, 2009.
3. Horner MJ, Ries LAG, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2006/, 2009.
4. American Cancer Society. Breast Cancer Facts & Figures 2009-2010, 2009.
5. National Cancer Institute. Genetics of breast and ovarian cancer (PDQ). http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page3, 2009.
6. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 336: 1401-8, 1997.
7. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 352: 1337-9, 1998.
8. Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 72(5):1117-30, 2003.
9. King MC, Marks JH and Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 302: 643-6, 2003.
10. Risch HA, McLaughlin JR, Cole DEC, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 98(23):1694-706, 2006.
11. Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among BRCA 1/2 carriers. JAMA. 299(2):194-201, 2008.
12. Jernström H, Lubinski J, Lynch HT, et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 96: 1094-8, 2004.
13. Jernström H, Lerman C, Ghadirian P, et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 354(9193):1846-50, 1999.
14. Friedman E, Kotsopoulos J, Lubinski J, et al. for the Hereditary Breast Cancer Clinical Study Group. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res. 8(2):R15, 2006.
15. Ghadirian P, Lubinski J, Lynch H, et al. Smoking and the risk of breast cancer among carriers of BRCA mutations. Int J Cancer. 110(3):413-6, 2004.
16. Ginsburg O, Ghadirian P, Lubinski J, et al. for the Hereditary Breast Cancer Clinical Study Group. Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. Breast Cancer Res Treat. 114(1):127-35, 2009.
17. Kotsopoulos J, Librach CL, Lubinski J, et al. for the Hereditary Breast Cancer Clinical Study Group. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control. 19(10):1111-9, 2008.
18. Rebbeck TR, Wang Y, Kantoff PW, et al. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res. 61(14):5420-4, 2001.
19. Cullinane CA, Lubinski J, Neuhausen SL, et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 117(6):988-91, 2005.
20. Chang-Claude J, Andrieu N, Rookus M, et al. for the Epidemiological Study of Familial Breast Cancer (EMBRACE), Gene Etude Prospective Sein Ovaire (GENEPSO), Genen Omgeving studie van de werkgroep Hereditiair Borstkanker Onderzoek Nederland (GEO-HEBON) and International BRCA1/2 Carrier Cohort Study (IBCCS) collaborators group. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev. 16(4):740-6, 2007.
21. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol. 25(25):3831-6, 2007.
22. Narod SA, Dubé MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 94(23):1773-9, 2002.
23. Milne RL, Osorio A, Ramón Y, et al. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2009 Apr 16. [Epub ahead of print]
24. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 22(12):2328-35, 2004.
25. Domchek SM and Weber BL. Chapter 17: Inherited Genetic Factors and Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 3rd edition. Lippincott Williams and Wilkins, 2004.
26. Ries LAG, Melbert D, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
27. Isaacs CJD, Peshkin BN, Schwartz M. Chapter 19: Evaluation and Management of Women with a Strong Family History, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 3rd edition. Lippincott Williams and Wilkins, 2004.
28. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 101(2):80-7, 2009.
29. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 352(9137):1337-9, 1998.
30. Giusti RM, Rutter JL, Duray PH, et al. A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet. 40: 787-92, 2003.
31. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 367(9510):595-604, 2006.
32. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 94: 1365-72, 2002.
33. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 22(4):735-42, 2004.
34. Kilbride KE and Newman LA. Chapter 25: Lobular Carcinoma In Situ: Clinical Management, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
35. Simpson PT, Reis-Filho JS, Lakhani SR. Chapter 24: Lobular Carcinoma In Situ: Biology and Pathology, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
36. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Breast cancer. V.1.200p. http://www.nccn.org, 2009.
37. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 28(4):400-18, 2001.
38. Houghton J, George WD, Cuzick J, et al. for the UK Coordinating Committee on Cancer Research (UKCCCR) Ductal Carcinoma in situ (DCIS) Working Party on behalf of DCIS Trialists in the UK, Australia, and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 362(9378):95-102, 2003.
39. Vogel VG, Constantino JP, Wickerham DL, et al. for the National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 295(23):2727-41, 2006.
40. Wickerham DL, Costantino JP, Vogel VG, et al. The use of tamoxifen and raloxifene for the prevention of breast cancer. Recent Results Cancer Res. 181:113-9, 2009.
41. Pharoah PDP, Day NE, Duggy S, Easton DF, Ponder BAJ. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 71(5):800-9, 1997.
42. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 358: 1389-99, 2001.
43. Willett WC, Tamimi RM, Hankinson SE, Hunter DJ, Colditz GA. Chapter 20: Nongenetic Factors in the Causation of Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
44. Anderson DE and Badzioch MD. Familial breast cancer risks. Effects of prostate and other cancers. Cancer. 72: 114-9, 1993.
45. Anderson DE and Badzioch MD. Familial effects of prostate and other cancers on lifetime breast cancer risk. Breast Cancer Res Treat. 28: 107-13, 1993.
46. Valeri A, Fournier G, Morin V, et al. Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives. Int J Cancer. 86: 883-7, 2000.
47. Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 99(15):1178-87, 2007.
48. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 356(3):227-36, 2007.
49. Pisano ED, Gatsonis C, Hendrick E, et al. for the Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 27;353(17):1773-83, 2005.
50. Hancock SL, Tucker MA and Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 85: 25-31, 1993.
51. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 18: 498-509, 2000.
52. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 290(4):465-75, 2003.
53. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 21(23):4386-94, 2003.
54. Kenney LB, Yasui Y, Inskip PD, et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med. 141(8):590-7, 2004.
55. Guibout C, Adjadu E, Rubino C. et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol. 23(1):197-204, 2005.
56. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 25(12):1489-97, 2007.
57. Feig SA. Adverse effects of screening mammography. Radiol Clin North Am. 42: 807-19, 2004.
58. Berrington de Gonzalez A, Reeves G. Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits. Br J Cancer. 93:590-6, 2005.
59. Gotzshe PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 18;(4):CD001877, 2006.
60. Tamimi RM, Byrne B, Baer H, et al. Benign breast disease, recent alcohol consumption, and risk of breast cancer: a nested case-control study. Breast Cancer Res. 7(4):R555-62, 2005.
61. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 353(3):229-37, 2005.
62. Worsham MJ, Abrams J, Raju U, Kapke A, et al. Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population. Breast J. 13(2):115-21, 2007.
63. Gao X, Fisher SG, Bahman Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 56(4):1038-45, 2003.
64. Trentham-Dietz A, Newcomb PA, Nichols HB, Hampton JM. Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res Treat. 105(2):195-207, 2007.
65. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 101(15):1058-65, 2009.
66. Innos K, Horn-Ross PL. Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 111(3):531-40, 2008.
67. Robinson D, Holmberg L, Møller H. The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. Br J Cancer. 99(4):611-5, 2008.
68. Horwich A, Swerdlow AJ. Second primary breast cancer after Hodgkin's disease. Br J Cancer. 90(2):294-8, 2004.
69. Nissen MJ, Lazovich D and Jolitz G. Breast carcinoma after cancer at another site: method of detection, tumor characteristics, and surgical treatment. Cancer. 89: 1999-2005, 2000.
70. Rosner B, Colditz GA and Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol. 139: 819-835, 1994.
71. Ewertz M, Duffy SW, Adami HO, et al. Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer. 46(4):597-603, 1990.
72. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 94(8): 606-616, 2002.
73. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 97(10):755-65, 2005.
74. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 98(19):1406-15, 2006.
75. Key T, Appleby P, Barnes I, Reeves G for the Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 94(8):606-16, 2002.
76. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer. 12(4):1071-82, 2005.
77. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 97(10):755-65, 2005.
78. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer. 90(1):153-9, 2004.
79. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 96(24):1856-65, 2004.
80. U.S. Food and Drug Administration. Menopause and hormone therapy. http://www.fda.gov/ForConsumers/ByAudience/ForWomen/ucm118624.htm.
81. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332: 1589-93, 1995.
82.Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 350: 1047-59, 1997.
83. Colditz GA and Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 152: 950-64, 2000.
84. Ross RK, Paganini-Hill A, Wan PC and Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 92:328-32, 2000.
85. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283:485-91, 2000.
86. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288(3):321-33, 2002.
87. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 362:419-27, 2003.
88. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 289:3243-53, 2003.
89. Chlebowski RT, Kuller LH, Prentice RL, et al. for the WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 360(6):573-87, 2009.
90. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 350:991-1004, 2004.
91. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 290:1729-38, 2003.
92. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 290:1739-48, 2003.
93. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 349:523-34, 2003.
94. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 289:2673-84, 2003.
95. Grady D. Postmenopausal hormones—therapy for symptoms only. N Engl J Med. 348(19):1835-7, 2003.
96. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med.348(19):1839-54, 2003.
97. Yaffe K, Sawaya G, Lieberburg I and Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 279:688-95, 1998.
98. Shumaker SA, Legault C, Thal L, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 289:2651-62, 2003.
99. Yaffe K. Hormone therapy and the brain: Deja vu all over again? JAMA. 289:2717-9, 2003.
100. Stefanick ML, Anderson GL, Margolis GL, et al. for the Women's Health Initiative Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 295(14):1647-57, 2006.
101. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and risk of invasive breast cancer. Arch Intern Med. 166(9):1027-1032, 2006.
102. Brinton LA, Richesson D, Leitzmann MF, et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev. 17(11):3150-60, 2008.
103. Lacey JV, Jr., Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 288:334-41, 2002.
104. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med. 168(8):861-6, 2008.
105. Anderson GL, Limacher M, Assaf AR, et al. for the Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Randomized Controlled Trial. JAMA. 291:1701-12, 2004.
106. Kerlikowske K, Shepherd J, Creasman J, Tice JA, Ziv E, Cummings SR. Are breast density and bone mineral density independent risk factors for breast cancer? J Natl Cancer Inst. 97(5):368-74, 2005.
107. Cauley JA, Lucas FL, Kuller LH, et al. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA. 276: 1404-8, 1996.
108. Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med. 336:611-7, 1997.
109. Zmuda JM, Cauley JA, Ljung BM, et al. Bone mass and breast cancer risk in older women: differences by stage at diagnosis. J Natl Cancer Inst. 336: 611-7, 2001.
110. Buist DS, LaCroix AZ, Barlow WE, et al. Bone mineral density and breast cancer risk in postmenopausal women. J Clin Epidemiol. 54:417-22, 2001.
111. Hadji P, Gottschalk M, Ziller V, Kalder M, Jackisch C, Wagner U. Bone mass and the risk of breast cancer: the influence of cumulative exposure to oestrogen and reproductive correlates. Results of the Marburg breast cancer and osteoporosis trial (MABOT). Maturitas. 56(3):312-21, 2007.
112. Chen Z, Arendell L, Aickin M, Cauley J, Lewis CE, Chlebowski R for the Women's Health Initiative Program, National Heart, Lung and Blood Institute, US Department of Health and Human Services. Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. Cancer. 113(5):907-15, 2008.
113. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 278: 1407-11, 1997.
114. Van den Brandt PA, Speigelman D, Yaun S, et al. Pooled Analysis of Prospective Cohort on Height, Weight, and Breast Cancer Risk. American Journal of Epidemiology. 152(6):514-527, 2000.
115. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 335(7630):1134, 2007.
116. Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA. 296(2):193-201, 2006.
117. Connolly BS, Barnett C, Vogt KN, et al. A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr Cancer. 44: 127-38, 2002.
118. Harvie M, Hooper L and Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev. 4: 157-73, 2003.
119. MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG. Body size and composition and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 13(12):2117-25, 2004.
120. Han D, Nie J, Bonner MR, et al. Lifetime adult weight gain, central adiposity, and the risk of pre- and postmenopausal breast cancer in the Western New York exposures and breast cancer study. Int J Cancer.119(12):2931-7, 2006.
121. Yost K, Perkins C, Cohen R, et al. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 12: 703-11, 2001.
122. Heck KE and Pamuk ER. Explaining the relation between education and postmenopausal breast cancer. Am J Epidemiol. 145: 366-72, 1997.
123. Braaten T, Weiderpass E, Kumle M, et al. Education and risk of breast cancer in the Norwegian-Swedish women's lifestyle and health cohort study. Int J Cancer. 110: 579-83, 2004.
124. Braaten T, Weiderpass E, Kumle M, Lund E. Explaining the socioeconomic variation in cancer risk in the Norwegian Women and Cancer Study. Cancer Epidemiol Biomarkers Prev. 14(11 Pt 1):2591-7, 2005.
125. Vidarsdottir H, Gunnarsdottir HK, Olafsdottir EJ, Olafsdottir GH, Pukkala E, Tryggvadottir L. Cancer risk by education in Iceland: a census-based cohort study. Acta Oncol. 47(3):385-90, 2008.
126. Fujino Y, Mori M, Tamakoshi A, et al. for the JACC Study Group. A prospective study of educational background and breast cancer among Japanese women. Cancer Causes Control. 19(9):931-7, 2008.
127. dos Santos Silva I and Beral V. Socioeconomic differences in reproductive behaviour. IARC Sci Publ: 285-308, 1997.
128. Egan KM, Newcomb PA, Longnecker MP, et al. Jewish religion and risk of breast cancer. Lancet. 347: 1645-6, 1996.
129. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 11: 198-200, 1995.
130. Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet. 14: 188-90, 1996.
131. Roa BB, Boyd AA, Volcik K and Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 14: 185-7, 1996.
132. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 64(4):963-70, 1999.
133. Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer—collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 87(11):1234-45, 2002.
134. Hunter DJ and Willett WC. Nutrition and breast cancer. Cancer Causes Control. 7: 56-68, 1996.
135. Zhang SM, Willett WC, Selhub J, et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst. 95(5):373-80, 2003.
136. Baglietto L, English DR, Gertig DM, Hopper JL, Giles GG. Does dietary folate intake modify effect of alcohol consumption on breast cancer risk? Prospective cohort study. BMJ. 331(7520):807, 2005.
137. Tjønneland A, Christensen J, Olsen A, et al. Folate intake, alcohol and risk of breast cancer among postmenopausal women in Denmark. Eur J Clin Nutr. 60(2):280-6, 2006.
138. Feigelson HS, Jonas CR, Robertson AS, McCullough ML, Thun MJ, Calle EE. Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 12(2):161-4, 2003.
139. Tjønneland A, Christensen J, Olsen A, et al. Alcohol intake and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control. 18(4):361-73, 2007.
140. Duffy CM, Assaf A, Cyr M, et al. Alcohol and folate intake and breast cancer risk in the WHI Observational Study. Breast Cancer Res Treat. 116(3):551-62, 2009.
141. Rockhill B, Willett WC, Hunter DJ, et al. A prospective study of recreational physical activity and breast cancer risk. Arch Intern Med. 159(19):2290-6, 1999.
142. McTiernan A, Kooperberg C, White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA. 290: 1331-6, 2003.
143. Tehard B, Friedenreich CM, Oppert JM, Clavel-Chapelon. Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study. Cancer Epidemiol Biomarkers Prev. 15(1):57-64, 2006.
144. Colditz GA and Stein CJ. Handbook of Cancer Risk Assessment and Prevention. Sudbury, MA: Jones and Bartlett, 2004.
145. International Agency for Research on Cancer (WHO): IARC Handbooks of Cancer Prevention, Volume 6: Weight Control and Physical Activity. IARC Press, Lyon, France, 2002.
146. McTiernan A, Wu L, Chen C, et al. for the Women's Health Initiative Investigators. Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity (Silver Spring). 14(9):1662-77, 2006.
147. Rogers CJ, Colbert LH, Greiner JW, Perkins SN, Hursting SD. Physical activity and cancer prevention: pathways and targets for intervention. Sports Med. 38(4):271-96, 2008.
148. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 293(20):2479-86, 2005.
149. Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 17(2):379-86, 2008.
150. Mutrie N, Campbell AM, Whyte F, et al. Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial. BMJ. 334(7592):517, 2007.
151. Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R, Roalfe A. Randomized trial of exercise therapy in women treated for breast cancer. J Clin Oncol. 25(13):1713-21, 2007.
152. Harris JR, Lippman ME, Veronesi U and Willett W. Breast cancer (1). N Engl J Med. 327:319-28, 1992.
153. Kelsey JL and Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health. 17:47-67, 1996.
154. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 8(4):R43, 2006.
155. Hankinson SE, Colditz GA, Manson JE, et al. A prospective study of oral contraceptive use and risk of breast cancer. Cancer Causes Control. 8:65-72, 1997.
156. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev. 11(11):1375-81, 2002.
157. Dumeaux V, Lund E, Hjartaker A. Use of oral contraceptives, alcohol, and risk for invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 13(8):1302-7, 2004.
158. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 347:1713-27, 1996.
159. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 346:2025-32, 2002.
160. Kawachi I, Colditz GA and Hankinson S. Long-term benefits and risks of alternative methods of fertility control in the United States. Contraception. 50:1-16, 1994.
161. Bosetti C, Negri E, Trichopoulos D, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer. 102(3):262-5, 2002.
162. Bigrigg A, Evans M, Gbolade B, et al. Depo Provera. Position paper on clinical use, effectiveness and side effects. Br J Fam Plann. 25(2):69-76, 1999.
163. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. New Product Review (September 2003). Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra). J Fam Plann Reprod Health Care. 30(1):43-5, 2004.
164. Skegg DC, Noonan EA, Paul C, et al. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. JAMA. 273(10):799-804, 1995.
165. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 93(20):1557-62, 2001.
166. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst. 93(20):1563-8, 2001.
167. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer. 41(13):2023-32, 2005.
168. Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. Night work and risk of breast cancer. Epidemiology. 17(1):108-11, 2006.
169. Davis S, Mirick DK. Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. Cancer Causes Control. 17(4):539-45, 2006.
170. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 152:514-27, 2000.
171. Bernier MO, Plu-Bureau G, Bossard N, et al. Breastfeeding and risk of breast cancer: a meta-analysis of published studies. Hum Reprod Update. 6:374-86, 2000.
172. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breast feeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet 20:187-95, 2002.
173. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 19;8(4):R43, 2006.
174. Colditz GA, Willett WC, Hunter DJ, et al. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA. 270:338-43, 1993.
175. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 98(17):1204-14, 2006.
176. Chen Y, Thompson W, Semenciw R and Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 8:855-61, 1999.
177. Degnim AC, Visscher DW, Berman HK, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. 25(19):2671-7, 2007.
178. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 94:606-16, 2002.
179. Trichopoulos D, MacMahon B and Cole P. Menopause and breast cancer risk. J Natl Cancer Inst. 48:605-13, 1972.
180. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA. 279:535-40, 1998.
181. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 16;97(6):439-48, 2005.
182. Gilliland FD, Hunt WC, Baumgartner KB, et al. Reproductive risk factors for breast cancer in Hispanic and non-Hispanic white women: the New Mexico Women's Health Study. Am J Epidemiol.148(7):683-92, 1998.
183. Aziz H, Hussain F, Sohn C, et al. Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol. 22:436-40, 1999.
184. Krieger N. Is breast cancer a disease of affluence, poverty, or both? The case of African American women. Am J Public Health. 92:611-3, 2002.
185. Johansen C. Electromagnetic fields and health effects—epidemiologic studies of cancer, diseases of the central nervous system and arrhythmia-related heart disease. Scand J Work Environ Health. 30 (Suppl 1):1-30, 2004.
186. American Cancer Society. Cancer Facts & Figures for African Americans: 2009-2010, 2009.
187. Gray GE, Henderson BE, Pike MC. Changing ratio of breast cancer incidence rates with age of black females compared with white females in the United States. J Natl Cancer Inst. 64:461-3, 1980.
188. Haiman CA, Pike MC, Bernstein L, et al. Ethnic differences in ovulatory function in nulliparous women. Br J Cancer. 86:367-71, 2002.
189. Wu T, Mendola P, Buck GM. Ethnic differences in the presence of secondary sex characteristics and menarche among US girls: the Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics. 110:752-7, 2002.
190. Anderson SE, Dallal GE, Must A. Relative weight and race influence average age at menarche: results from two nationally representative surveys of US girls studied 25 years apart. Pediatrics. 111:844-50, 2003.
191. Jones BA, Kasl SV, Howe CL, et al. African-American/White differences in breast carcinoma: p53 alteration and other tumor characteristics. Cancer. 101: 1293-1301, 2004.
192. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 110(4):876-84, 2007.
193. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 295(21):2492-502, 2006.
194. Ihemelandu CU, Leffall LD Jr, Dewitty RL, et al. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol. 14(10):2994-3003, 2007.
195. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 109(1):123-139, 2008.
196. Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL. Early onset of breast cancer in a group of British black women. Br J Cancer. 98(2):277-81, 2008.
197. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 113(2):357-70, 2009.
198. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast cancer screening and diagnosis. V.1.2009, 2009.
199. Schrag D, Kuntz KM, Garber JE and Weeks JC. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 336:1465-71, 1997.
200. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 340:77-84, 1999.
201. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 93:1633-7, 2001.
202. Calderon-Margalit R, Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer. 112(3):357-64, 2004.
203. Geiger Am, Yu O, Herrinton LJ, et al. A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices. Arch Intern Med. 165(5):516-20, 2005.
204. Grann VR, Jacobson JS, Thomason D, et al. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol. 20:2520-9, 2002.
205. van Roosmalen MS, Verhoef LC, Stalmeier PF, et al. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J Clin Oncol. 20:2092-100, 2002.
206. Frost MH, Schaid DJ, Sellers TA, et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA. 284:319-24, 2000.
207. Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. (4):CD002748, 2004.
208. Barton MB, West CN, Liu IL, et al. Complications following bilateral prophylactic mastectomy. J Natl Cancer Inst Monogr. (35):61-6, 2005.
209. Struewing JP, Watson P, Easton DF, et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr: 33-5, 1995.
210. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 91:1475-9, 1999.
211. Schrag D, Kuntz KM, Garber JE and Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA. 283:617-24, 2000.
212. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 346:1609-15, 2002.
213. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346:1616-22, 2002.
214. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 7(3):223-9, 2006.
215. NIH Consensus Development Panel on Ovarian Cancer. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA. 273(6):491-7, 1995.
216. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment: Breast and ovarian, V.1.2009, 2009.
217. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 97(22):1652-62, 2005.
218. Cuzick J, Forbes JF, Sestak I, et al. for the International Breast Cancer Intervention Study I (IBIS-I) Investigators. Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 21;99(4):272-82, 2007.
219. Veronesi U, Maisonneuve P, Rotmensz N, et al. for the Italian Tamoxifen Study Group. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 99(9):727-37, 2007.
220. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 65:125-34, 2001.
221. Martino S, Cauley JA, Barrett-Connor E, et al. for the CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 96(23):1751-1761, 2004.
222. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 355(2):125-37, 2006.
223. Kinsinger LS, Harris R, Woolf SH, et al. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 137:59-69, 2002.
224. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 361:296-300, 2003.
225. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 101(1):113-21, 2007.
226. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 356:1876-81, 2000.
227. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 286:2251-6, 2001.
228. Loman N, Johannsson O, Bendahl PO, et al. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer. 83:310-9, 1998.
229. Gromwald J, Tung N, Foulkes WD, et al. for the Hereditary Breast Cancer Clinical Study Group. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer.118(9):2281-4, 2006.
230. Wrensch M, Petrakis NL, King EB, et al. Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy. Am J Epidemiol. 137:829-33, 1993.
231. Fabian CJ, Kimler BF, Zalles CM, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst. 92:1217-27, 2000.
232. Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 93:624-32, 2001.
233. Khan SA. The role of ductal lavage in the management of women at high risk for breast carcinoma. Curr Treat Options Oncol. 5(2):145-51, 2004.
234. Kurian AW, Mills MA, Jaffee M, et al. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Cancer Epidemiol Biomarkers Prev. 14(5):1082-9, 2005.
235. Higgins SA, Matloff ET, Rimm DL, et al. Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer. Breast Cancer Res. 7(6):R1017-22, 2005.
236. Euhus DM, Bu D, Milchgrub S, et al. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 17(5):1051-9, 2008.
237. Hunter DJ, Spiegelman D, Adami HO, et al. Cohort studies of fat intake and the risk of breast cancer—a pooled analysis. N Engl J Med. 334:356-61, 1996.
238. Smith-Warner SA, Speigelman D, Adami HO, et al. Types of dietary fat and breast cancer: a pooled analysis of cohort studies. Int J Cancer. 92:767-774, 2001.
239. Boyd NF, Stone J, Vogt KN, Connelly BS, Martin LJ, Minkin S. Dietary fat and breast cancer risk revisited: a meta-analysis of the published literature. Br J Cancer. 89(9):1672-85, 2003.
240. Kim EHJ, Willett WC, Colditz GA, et al. Dietary Fat and Risk of Postmenopausal Breast Cancer in a 20-year Follow-up. Am J Epidemiol. 164(10):990-7, 2006.
241. Prentice RL, Chlebowski RT, Patterson R, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 295(6):629-42, 2006.
242. Sieri S, Krogh V, Ferrari P, et al. Dietary fat and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 88(5):1304-12, 2008.
243. Willett WC. Specific fatty acids and risks of breast and prostate cancer: dietary intake. Am J Clin Nutr. 66:1557S-1563S, 1997.
244. Cho E, Spiegelman D, Hunter DJ, et al. Premenopausal fat intake and risk of breast cancer. J Natl Cancer Inst. 95:1079-85, 2003.
245. Willett WC, Hunter DJ, Stampfer MJ, et al. Dietary fat and fiber in relation to risk of breast cancer. JAMA. 268(15):2037-2044, 1992.
246. Wolk A, Bergstrom R, Hunter D, et al. A prospective study of association of monounsaturated fat and other types of fat with risk of breast cancer. Arch Intern Med. 158:41-5, 1998.
247. Hunter DJ, Manson JE, Colditz GA, et al. A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. N Engl J Med. 329:234-40, 1993.
248. Sieri S, Krogh V, Pala V, et al. Dietary patterns and risk of breast cancer in the ORDET cohort. Cancer Epidemiol Biomarkers Prev. 13(4):567-72, 2004.
249. Fung TT, Hu FB, Holmes MD, et al. Dietary patterns and the risk of postmenopausal breast cancer. Int J Cancer. 116(1):116-21, 2005.
250. Cui Y, Shikany JM, Liu S, Shagufta Y, Rohan TE. Selected antioxidants and risk of hormone receptor-defined invasive breast cancers among postmenopausal women in the Women's Health Initiative Observational Study. Am J Clin Nutr. 87(4):1009-18, 2008.
251. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA. 285:769-76, 2001.
252. Sato R, Helzlsouer KJ, Alberg AJ, et al. Prospective study of carotenoids, tocopherols, and retinoid concentrations and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 11:451-457, 2002.
253. Tamimi RM, Hankinson SE, Campos H, et al. Plasma carotenoids, retinol, and tocopherols and risk of breast cancer. Am J Epidemiol. 161(2):153-60, 2005.
254. Sesso HD, Buring JE, Zhang SM, et al. Dietary and plasma lycopene and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 14(5):1074-81, 2005.
255. Lawlor DA, Smith GD and Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control. 15:267-75, 2004.
256. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 101(1):48-60, 2009.
257. Kabat GC, Kim M, Caan BJ, et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer. 125(11):2704-10, 2009.
258. Verheus M, Peeters PH, Rinaldi S, et al. Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 119(3):659-67, 2006.
259. Michels KB, Solomon CG, Hu FB, et al. for the Nurses' Health Study. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care. 26(6):1752-8, 2003.
260. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res Treat. 98(3):349-56, 2006.
261. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 121(4):856-62, 2007.
262. Del Giudice ME, Fantus IG, Ezzat S, et al. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat. 47:111-20, 1998.
263. Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE. Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev. 16(1):161-4, 2007.
264. Augustin LS, Dal Maso L, La Vecchia C, et al. Dietary glycemic index and glycemic load, and breast cancer risk: a case-control study. Ann Oncol. 12:1533-8, 2001.
265. Lajous M, Willett W, Lazcano-Ponce E, et al. Glycemic load, glycemic index, and the risk of breast cancer among Mexican women. Cancer Causes Control. 16(10):1165-9, 2005.
266. Tavani A, Giordano L, Gallus S, et al. Consumption of sweet foods and breast cancer risk in Italy. Ann Oncol. 17(2):341-5, 2006.
267. Jonas CR, McCullough ML, Teras LF, et al. Dietary glycemic index, glycemic load, and risk of incident breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 12(6):573-7, 2003.
268. Higginbotham S, Zhang ZF, Lee IM, et al. Dietary glycemic load and breast cancer risk in the Women's Health Study. Cancer Epidemiol Biomarkers Prev. 13(1):65-70, 2004.
269. Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE. Dietary carbohydrates and breast cancer risk: a prospective study of the roles of overall glycemic index and glycemic load. Int J Cancer. 114(4):653-8, 2005.
270. Mulholland HG, Murray LJ, Cardwell CR, Cantwell MM. Dietary glycaemic index, glycaemic load and breast cancer risk: a systematic review and meta-analysis. Br J Cancer. 99(7):1170-5, 2008.
271. Larsson SC, Bergkvist L, Wolk A. Glycemic load, glycemic index and breast cancer risk in a prospective cohort of Swedish women. Int J Cancer. 125(1):153-7, 2009.
272. Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst. 98(7):459-71, 2006.
273. Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer. 98(1):9-14, 2008.
274. Lee SA, Shu XO, Li H, et al. Adolescent and adult soy food intake and breast cancer risk: results from the Shanghai Women's Health Study. Am J Clin Nutr. 89(6):1920-6, 2009.
275. Hsieh CY, Santell RC, Haslam SZ and Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 58:3833-8, 1998.
276. Allred CD, Allred KF, Ju YH, et al. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 61:5045-50, 2001.
277. Allred CD, Ju YH, Allred KF, et al. Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcinogenesis. 22:1667-73, 2001.
278. Moorman PG, Terry PD. Consumption of dairy products and the risk of breast cancer: a review of the literature. Am J Clin Nutr. 80:5-14, 2004.
279. Ganmaa D, Sato A. The possible role of female sex hormones in milk from pregnant cows in the development of breast, ovarian and corpus uteri cancers. Med Hypotheses. 65:1028-37, 2005.
280. Chlebowski RT, Johnson KC, Kooperberg C, et al. for the Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 100(22):1581-91, 2008.
281. Missmer SA, Smith-Warner SA, Spiegelman D, et al. Meat and dairy food consumption and breast cancer: a pooled analysis of cohort studies. Int J Epidemiol. 31:78-85, 2002.
282. Cho E, Spiegelman D, Hunter DJ, et al. Premenopausal fat intake and risk of breast cancer. J Natl Cancer Inst. 95:1079-85, 2003.
283. McCullough ML, Rodriguez C, Diver WR, et al. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 14(12):2898-904, 2005.
284. Lin J, Manson JE, Lee IM, Cook NR, Buring JE, Zhang SM. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med. 167(10):1050-9, 2007.
285. Blackmore KM, Lesosky M, Barnett H, Raboud JM, Vieth R, Knight JA. Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Am J Epidemiol. 168(8):915-24, 2008.
286. Gissel T, Rejnmark L, Mosekilde L, Vestergaard P. Intake of vitamin D and risk of breast cancer--a meta-analysis. J Steroid Biochem Mol Biol. 111(3-5):195-9, 2008.
287. Chlebowski RT, Johnson KC, Kooperberg C, for the Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 100(22):1581-91, 2008.
288. Kuper H, Yang L, Sandin S, Lof M, Adami HO, Weiderpass E. Prospective study of solar exposure, dietary vitamin D intake, and risk of breast cancer among middle-aged women. Cancer Epidemiol Biomarkers Prev. 18(9):2558-61, 2009.
289. Doyle C, Kushi LH, Byers T, et al. for the 2006 Nutrition, Physical Activity and Cancer Survivorship Advisory Committee. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin. 56(5):323-353, 2006.
290. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 25(12):1482-8, 2007.
291. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 363(9418):1346-7, 2004.
292. Shi R, Yu H, McLarty J and Glass J. IGF-I and breast cancer: a meta-analysis. Int J Cancer. 111:418-23, 2004.
293. Rinaldi S, Peeters PH, Berrino F, et al. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 13(2):593-605, 2006.
294. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 14(3):699-704, 2005.
295. Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 16(4):763-8, 2007.
296. Hamajima N, Hirose K, Tajima K, et al. for the Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer—collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 87(11):1234-45, 2002.
297. Al-Delaimy WK, Cho E, Chen WY, Colditz GA, Willet WC. A prospective study of smoking and risk of breast cancer in young adult women. Cancer Epidemiol Biomarkers Prev. 13(3):398-404, 2004.
298. U.S. Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004.
299. U.S. Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2006.
300. Reynolds P, Hurley S, Goldberg DE, et al. Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. J Natl Cancer Inst. 96:29-37, 2004.
301. Gram IT, Braaten T, Terry PD, et al. Breast cancer risk among women who start smoking as teenagers. Cancer Epidemiol Biomarkers Prev. 14:61-6, 2005.
302. Hanaoka T, Yamamoto S, Sobue T, Sasaki S, Tsugane S. Active and passive smoking and breast cancer risk in middle-aged Japanese women. Int J Cancer. 114:317-22, 2005.
303. Cui Y, Miller AB, Rohan TE. Cigarette smoking and breast cancer risk: update of a prospective cohort study. Breast Cancer Res Treat. 100(3):293-9, 2006.
304. Lawlor DA, Ebrahim S, Smith GD. Smoking before the birth of a first child is not associated with increased risk of breast cancer: findings from the British Women's Heart and Health Cohort Study and a meta-analysis. Br J Cancer. 91:512-8, 2004.
305. Reynolds P, Hurley SE, Hoggatt K, et al. Correlates of active and passive smoking in the California Teachers Study cohort. J Womens Health (Larchmt). 13:778-90, 2004.
306. Ambrosone CB, Kropp S, Yang J, Yao S, Shields PG, Chang-Claude J. Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis. Cancer Epidemiol Biomarkers Prev. 17(1):15-26, 2008.
307. Reynolds P, Hurley S, Goldberg DE, et al. Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. J Natl Cancer Inst. 96(1):29-37, 2004.
308. Egan KM, Stampfer MJ, Hunter D, et al. Active and passive smoking in breast cancer: prospective results from the Nurses' Health Study. Epidemiology. 13(2):138-45, 2002.
309. Miller MD, Marty MA, Broadwin R, et al. The association between exposure to environmental tobacco smoke and breast cancer: A review by the California Environmental Protection Agency. Prev Med. Prev Med. 44(2):93-106, 2007.
310. Pirie K, Beral V, Peto R, Roddam A, Reeves G, Green J for the Million Women Study Collaborators. Passive smoking and breast cancer in never smokers: prospective study and meta-analysis. Int J Epidemiol. 37(5):1069-79, 2008.
311. Gammon MD, Eng SM, Teitelbaum SL, et al. Environmental tobacco smoke and breast cancer incidence. Environ Res. 96:176-85, 2004.
312. Shrubsole MJ, Gao YT, Dai Q, et al. Passive smoking and breast cancer risk among non-smoking Chinese women. Int J Cancer. 110:605-9, 2004.
313. Cho E, Chen WY, Hunter DJ, et al. Red meat intake and risk of breast cancer among premenopausal women. Arch Intern Med. 166(20):2253-9, 2006.
314. Zheng W, Gustafson DR, Sinha R, et al. Well-done meat intake and the risk of breast cancer. J Natl Cancer Inst. 90:1724-9, 1998.
315. Dai Q, Shu XO, Jin F, Gao YT, Ruan ZX, Zheng W. Consumption of animal foods, cooking methods, and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 11:801-8, 2002.
316. Kabat GC, Cross AJ, Park Y, et al. Meat intake and meat preparation in relation to risk of postmenopausal breast cancer in the NIH-AARP diet and health study. Int J Cancer. 124(10):2430-5, 2009.
317. Knekt P, Adlercreutz H, Rissanen H, Aromaa A, Teppo L, Heliovaara M. Does antibacterial treatment for urinary tract infection contribute to the risk of breast cancer? Br J Cancer. 82:1107-10, 2000.
318. Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer. JAMA. 291:827-35, 2004.
319. Sorensen HT, Skriver MV, Friis S, McLaughlin JK, Blot WJ, Baron JA. Use of antibiotics and risk of breast cancer: a population-based case-control study. Br J Cancer. 92:594-6, 2005.
320. Kaye JA, Jick H. Antibiotics and the risk of breast cancer. Epidemiology. 16:688-90, 2005.
321. Friedman GD, Oestreicher N, Chan J, Quesenberry CP Jr., Udaltsova N, Habel LA. Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women. Cancer Epidemiol Biomarkers Prev. 15(11):2102-6, 2006.
322. Garcia Rodriguez LA, Gonzalez-Perez A. Use of antibiotics and risk of breast cancer. Am J Epidemiol. 161:616-9, 2005.
323. Takkouche B, Regueira-Méndez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst. 100(20):1439-47, 2008.
324. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 99(8):608-15, 2007.
325. Gierach GL, Lacey JV Jr., Schatzkin A, et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res. 2008;10(2):R38.
326. Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. Arch Intern Med. 169(2):115-21, 2009.
327. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 294(1):47-55, 2005.
328. Darbre PD. Underarm cosmetics and breast cancer. J Appl Toxicol. 23:89-95, 2003.
329. Golden R, Gandy J, Vollmer G. A review of the endocrine activity of parabens and implications for potential risks to human health. Crit Rev Toxicol. 35:435-58, 2005.
330. Beijerinck D, van Noord PA, Kemmeren JM, Seidell JC. Breast size as a determinant of breast cancer. Int J Obes Relat Metab Disord. 19:202-5, 1995.
331. Franceschi S, Favero A, La Vecchia C, et al. Body size indices and breast cancer risk before and after menopause. Int J Cancer. 67:181-6, 1996.
332. Tavani A, Pregnolato A, La Vecchia C, Negri E, Favero A, Franceschi S. Breast size and breast cancer risk. Eur J Cancer Prev. 5:337-42, 1996.
333. Egan KM, Newcomb PA, Titus-Ernstoff L, et al. The relation of breast size to breast cancer risk in postmenopausal women (United States). Cancer Causes Control. 10:115-8, 1999.
334. Nagata C, Matsubara T, Fujita H, et al. Mammographic density and the risk of breast cancer in Japanese women. Br J Cancer. 92:2102-6, 2005.
335. Kusano AS, Trichopoulos D, Terry KL, Chen WY, Willett WC, Michels KB. A prospective study of breast size and premenopausal breast cancer incidence. Int J Cancer. 118(8):2031-4, 2006.
336. Thurfjell E, Hsieh CC, Lipworth L, Ekbom A, Adami HO, Trichopoulos D. Breast size and mammographic pattern in relation to breast cancer risk. Eur J Cancer Prev. 5:37-41,1996.
337. Ganmaa D, Willett WC, Li TY, et al. Coffee, tea, caffeine and risk of breast cancer: a 22-year follow-up. Int J Cancer. 122(9):2071-6, 2008.
338. Ishitani K, Lin J, Manson JE, Buring JE, Zhang SM. Caffeine consumption and the risk of breast cancer in a large prospective cohort of women. Arch Intern Med. 168(18):2022-31, 2008.
339. Feychting M, Ahlbom A, Kheifets L. EMF and Health. Annu Rev Public Health. 26:165-89, 2005.
340. Moulder JE, Foster KR, Erdreich LS, McNamee JP. Mobile phones, mobile phone base stations and cancer: a review. Int J Radiat Biol. 81:189-203, 2005.
341. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet. 354:1586-90, 1999.
342. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril. 71:853-9, 1999.
343. Ricci E, Parazzini F, Negri E, Marsico S, La Vecchia C. Fertility drugs and the risk of breast cancer. Hum Reprod. 14:1653-5, 1999.
344. Burkman RT, Tang MT, Malone KE, et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. Fertil Steril. 79:844-51, 2003.
345. Gauthier E, Paoletti X, Clavel-Chapelon F. Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study. Hum Reprod. 19:2216-21, 2004.
346. Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomarkers Prev. 16(7):1400-7, 2007.
347. Michels KB, Rosner BA, Chumlea WC, Colditz GA, Willett WC. Preschool diet and adult risk of breast cancer. Int J Cancer. 118(3):749-54, 2005.
348. Rosenberg L, Boggs DA, Adams-Campbell LL, Palmer JR. Hair relaxers not associated with breast cancer risk: evidence from the black women's health study. Cancer Epidemiol Biomarkers Prev. 16(5):1035-7, 2007.
349. Perkins CI, Hotes J, Kohler BA, Howe HL. Association between breast cancer laterality and tumor location, United States, 1994-1998. Cancer Causes Control. 15:637-45, 2004.
350. Cerhan JR, Folsom AR, Potter JD, Prineas RJ. Handedness and mortality risk in older women. Am J Epidemiol. 140:368-74, 1994.
351. Pavia M, Hsieh CC, Ekbom A, Adami HO, Trichopoulos D. Handedness, age at menarche, and age at menopause. Obstet Gynecol. 83:579-82, 1994.
352. Stellman SD, Wynder EL, DeRose DJ, Muscat JE. The epidemiology of left-handedness in a hospital population. Ann Epidemiol. 7:167-71, 1997.
353. Ramadhani MK, Elias SG, van Noord PA, Grobbee DE, Peeters PH, Uiterwaal CS. Innate left handedness and risk of breast cancer: case-cohort study. BMJ. 331(7521):882-3, 2005.
354. Mathes RW, Malone KE, Daling JR, et al. Migraine in postmenopausal women and the risk of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 17(11):3116-22, 2008.
355. Li CI, Mathes RW, Malone KE, et al. Relationship between migraine history and breast cancer risk among premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev. 18(7):2030-4, 2009.
356. Roberts FD, Newcomb PA, Trentham-Dietz A, Storer BE. Self-reported stress and risk of breast cancer. Cancer. 77:1089-93, 1996.
357. Lillberg K, Verkasalo PK, Kaprio J, Teppo L, Helenius H, Koskenvuo M. Stress of daily activities and risk of breast cancer: a prospective cohort study in Finland. Int J Cancer. 91: 888-93, 2001.
358. Duijts SF, Zeegers MP, Borne BV. The association between stressful life events and breast cancer risk: a meta-analysis. Int J Cancer. 107:1023-9, 2003.
359. Lillberg K, Verkasalo PK, Kaprio J, Teppo L, Helenius H, Koskenvuo M. Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am J Epidemiol. 157:415-23, 2003.
360. Schernhammer ES, Hankinson SE, Rosner B, et al. Job stress and breast cancer risk: the Nurses' Health Study. Am J Epidemiol. 160:1079-86, 2004.
361. Kroenke CH, Hankinson SE, Schernhammer ES, Colditz GA, Kawachi I, Holmes MD. Caregiving stress, endogenous sex steroid hormone levels, and breast cancer incidence. Am J Epidemiol. 159:1019-27, 2004.
362. Green A, Willett WC, Colditz GA, et al. Use of permanent hair dyes and risk of breast cancer. Journal of the National Cancer Institute. 79(2):253-257, 1987.
363. Thun MJ, Altekruse SF, Namboodiri MM, et al. Hair dye use and risk of fatal cancer in U.S. women. J Natl Cancer Inst. 86(3):210-215, 1994.
364. Cook LS, Malone KE, Daling JR, et al. Hair product use and the risk of breast cancer in young women. Cancer Causes Control. 10(6):551-559, 1999.
365. Takkouche B, Etminan M, Montes-Martinez A. Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA. 293(20):2516-25, 2005.
366. Beral V, Bull D, Doll R, et al. for the Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83 000 women with breast cancer from 16 countries. Lancet. 363:1007-16, 2004.
367. National Cancer Institute (NCI). Summary Report: Early Reproductive Events and Breast Cancer Workshop. http://www.cancer.gov/cancerinfo/ere-workshop-report, 2003.
368. Brind J, Chinchilli VM, Severs WB and Summy-Long J. Induced abortion as an independent risk factor for breast cancer: a comprehensive review and meta-analysis. J Epidemiol Community Health. 50:481-96, 1996.
369. Harris BM, Eklund G, Meirik O, et al. Risk of cancer of the breast after legal abortion during first trimester: a Swedish register study. BMJ. 299:1430-2, 1989.
370. Sellers TA, Potter JD, Severson RK, et al. Difficulty becoming pregnant and family history as interactive risk factors for postmenopausal breast cancer: the Iowa Women's Health Study. Cancer Causes Control. 4(1):21-8, 1993.
371. Calle EE, Mervis CA, Wingo PA, et al. Spontaneous abortion and risk of fatal breast cancer in a prospective cohort of United States women. Cancer Causes Control. 6(5):460-8, 1995.
372. Melbye M, Wohlfahrt J, Olsen JH, et al. Induced abortion and the risk of breast cancer. N Engl J Med. 336:81-5, 1997.
373. Lazovich D, Thompson JA, Mink PJ, et al. Induced abortion and breast cancer risk. Epidemiology. 11:76-80, 2000.
374. Henderson KD, Sullivan-Halley J, Reynolds P, et al. Incomplete pregnancy is not associated with breast cancer risk: the California Teachers Study. Contraception. 77(6):391-6, 2008.
375. Ye Z, Gao DL, Qin Q, Ray RM, Thomas DB. Breast cancer in relation to induced abortion in a cohort of Chinese women. Br J Cancer. 87(9):977-81, 2002.
376. Paoletti X, Clavel-Chapelon F. Induced and spontaneous abortion and breast cancer risk: results from the E3N cohort study. Int J Cancer. 106(2):270-6, 2003.
377. Palmer JR, Wise LA, Adams-Campbell LL, Rosenberg L. A prospective study of induced abortion and breast cancer in African-American women. Cancer Causes Control. 15(2):105-11, 2004.
378. Reeves GK, Kan SW, Key T, et al. Breast cancer risk in relation to abortion: Results from the EPIC study. Int J Cancer. 119(7):1741-5, 2006.
379. Michels KB, Xue F, Colditz GA, Willett WC. Induced and spontaneous abortion and incidence of breast cancer among young women: a prospective cohort study. Arch Intern Med. 167(8):814-20, 2007.
380. Caplan LS, Schoenfeld ER, O'Leary ES, et al. Breast cancer and electromagnetic fields—a review. Ann Epidemiol. 10:31-44, 2000.
381. Verkasalo PK, Pukkala E, Kaprio J, et al. Magnetic fields of high voltage power lines and risk of cancer in Finnish adults: Nationwide cohort study. Br Med J. 313:1047-1051, 1996.
382. Laden F, Neas LM, Tobert PE, et al. Electric blanket usage in the Nurses' Health Study. Am J Epidemiol. 152(1):41-49, 2000.
383. Kabat GC, O'Leary ES, Schoenfeld ER, et al. for the Electromagnetic Fields and Breast Cancer on Long Island Study Group. Electric blanket use and breast cancer on Long Island. Epidemiology. 14(5):514-20, 2003.
384. Forssén UM, Rutqvist LE, Ahlbom A, Feychting M. Occupational magnetic fields and female breast cancer: a case-control study using Swedish population registers and new exposure data. Am J Epidemiol. 161(3):250-9, 2005.
385. Feychting M, Forssen U. Electromagnetic fields and female breast cancer. Cancer Causes Control. 17(4):553-8, 2006.
386. Johansen C, Nielsen OR, Olsen JH, Schüz J. Risk for leukaemia and brain and breast cancer among Danish utility workers: a second follow-up. Occup Environ Med. 64(11):782-4, 2007.
387. Ray RM, Gao DL, Li W, et al. Occupational exposures and breast cancer among women textile workers in Shanghai. Epidemiology.18(3):383-92, 2007.
388. Laden F, Collman G, Iwamoto K, et al. 1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene and polychlorinated biphenyls and breast cancer: combined analysis of five U.S. studies. J Natl Cancer Inst. 93:768-76, 2001.
389. Laden F and Hunter DJ. Environmental risk factors and female breast cancer. Annu Rev Public Health. 19:101-23, 1998.
390. Gammon MD, Wolff MS, Neugut AI, et al. Environmental toxins and breast cancer on Long Island. II. Organochlorine compound levels in blood. Cancer Epidemiol Biomarkers Prev. 11:686-97, 2002.
391. Lopez-Cervantes M, Torres-Sanchez L, Tobias A, Lopez-Carrillo L. Dichlorodiphenyldichloroethane burden and breast cancer risk: a meta-analysis of the epidemiologic evidence. Environ Health Perspect. 112(2):207-14, 2004.
392. Raaschou-Nielsen O, Pavuk M, LeBlanc A, et al. Adipose organochlorine concentrations and risk of breast cancer among postmenopausal Danish women. Cancer Epidemiol Biomarkers Prev. 14(1):67-74, 2005.
393. Iwasaki M, Inoue M, Sasazuki S, et al. for the Japan Public Health Center-based Prospective Study Group. Plasma organochlorine levels and subsequent risk of breast cancer among Japanese women: a nested case-control study. Sci Total Environ. 402(2-3):176-83, 2008.
394. Clarke CA, Glaser SL, West DW, et al. Breast cancer incidence and mortality trends in an affluent population: Marin County, California, USA, 1990-1999. Breast Cancer Res. 4: R13, 2002.
395. Bryant H, Brasher P. Breast implants and breast cancer—reanalysis of a linkage study. N Engl J Med. 332(23):1535-9, 1995.
396. Brinton LA, Lubin JH, Burich MC, et al. Breast cancer following augmentation mammoplasty (United States). Cancer Causes Control. 11(9):819-27, 2000.
397. Hoshaw SJ, Klein PJ, Clark BD, Cook RR, Perkins LL. Breast implants and cancer: causation, delayed detection, and survival. Plast Reconstr Surg. 107(6):1393-407, 2001.
398. McLaughlin JK, Lipworth L, Fryzek JP, et al. Long-term cancer risk among Swedish women with cosmetic breast implants: an update of a nationwide study. J Natl Cancer Inst. 98(8):557-60, 2006.
399. Brisson J, Holowaty EJ, Villeneuve PJ, et al. Cancer incidence in a cohort of Ontario and Quebec women having bilateral breast augmentation. Int J Cancer. 118(11):2854-62, 2006.
400. Brinton LA, Brown SL, Colton T, et al. Characteristics of a population of women with breast implants compared with women seeking other types of plastic surgery. Plast Reconstr Surg. 105(3):919-27, 2000.
401. Friis S, Holmich LR, McLaughlin JK, et al. Cancer risk among Danish women with cosmetic breast implants. Int J Cancer. 118(4):998-1003, 2006.
402. Deapen DM, Hirsch EM, Brody GS. Cancer risk among Los Angeles women with cosmetic breast implants. Plast Reconstr Surg. 119(7):1987-92, 2007.
403. Hsieh CC, Trichopoulos D. Breast size, handedness and breast cancer risk. Eur J Cancer. 27:131-5, 1991.
404. Mirick DK, Davis S and Thomas DB. Antiperspirant use and the risk of breast cancer. J Natl Cancer Inst. 94:1578-80, 2002.
405. Gikas PD, Mansfield L, Mokbel K. Do underarm cosmetics cause breast cancer? Int J Fertil Womens Med. 49:212-4, 2004.
406. Lee AH. Why is carcinoma of the breast more frequent in the upper outer quadrant? A case series based on needle core biopsy diagnoses. Breast. 14:151-2, 2005.
407. Hatch EE, Palmer JR, Titus-Ernstoff L, et al. Cancer risk in women exposed to diethylstilbestrol in utero. JAMA. 280(7):630-4, 1998.
408. Palmer JR, Hatch EE, Rosenburg CL, et al. Risk of breast cancer in women exposed to diethylstilbestrol in utero: prelimiinary results (United States). Cancer Causes Control. 2002 Oct;13(8):753-8, 2002.
409. Palmer JR, Wise LA, Hatch EE, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 15(8):1509-14, 2006.
Updated 11/10/09
